Protein engineering combined with combinatorial optimization of critical synthetase cluster for efficient production of 1-Deoxynojirimycin in B. amyloliquefaciens.

Abstract excerpt

1-Deoxynojirimycin (1-DNJ) is a potent α-glucosidase inhibitor and a highly promising next-generation hypoglycemic agent, however, the catalytic efficiencies of its critical synthetases GabT1, YktC1 and GutB1 (TYB) are relatively low, which severely limits its large-scale production, and this research aimed to establish a cost-effective microbial cell factory for 1-DNJ production by integrating protein and...

Topics

Join the communities discussing this publication.

• 1-Deoxynojirimycin
• Ligases
• Mutation
• Protein Engineering